Search results for "biotechnologies"

showing 10 items of 20 documents

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Expression profiling of prospero in the Drosophila larval chemosensory organ: Between growth and outgrowth

2010

AbstractBackgroundThe antenno-maxilary complex (AMC) forms the chemosensory system of theDrosophilalarva and is involved in gustatory and olfactory perception. We have previously shown that a mutant allele of the homeodomain transcription factor Prospero (prosVoila1,V1), presents several developmental defects including abnormal growth and altered taste responses. In addition, many neural tracts connecting the AMC to the central nervous system (CNS) were affected. Our earlier reports on larval AMC did not argue in favour of a role ofprosin cell fate decision, but strongly suggested thatproscould be involved in the control of other aspect of neuronal development. In order to identify these fu…

Central Nervous SystemMESH : Transcription FactorsMESH: DrosophilaOF-FUNCTION SCREEN;MUSCA-DOMESTICA L;HOUSE-FLY LARVA;FINE-STRUCTURE;AXON GUIDANCE;TRANSCRIPTION FACTOR;PATTERN-FORMATION;GENETIC-ANALYSIS;NERVOUS-SYSTEMGenes InsectMESH: Genes InsectAXON GUIDANCEMUSCA-DOMESTICA L0302 clinical medicineMESH: Gene Expression Regulation DevelopmentalCluster AnalysisDrosophila ProteinsMESH: AnimalsTRANSCRIPTION FACTORMESH: Nerve Tissue ProteinsMESH : Nerve Tissue ProteinsOF-FUNCTION SCREENOligonucleotide Array Sequence AnalysisGenetics0303 health sciencesMESH : Central Nervous SystemMicrobiology and ParasitologyMESH : Genes InsectGene Expression Regulation DevelopmentalNuclear ProteinsMESH: Transcription FactorsNull alleleMicrobiologie et ParasitologieMESH : Oligonucleotide Array Sequence Analysis[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Larva[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]DrosophilaDrosophila ProteinResearch ArticleBiotechnologylcsh:QH426-470MESH: Drosophila Proteinslcsh:BiotechnologyNerve Tissue ProteinsBiotechnologiesBiology03 medical and health sciencesMESH: Gene Expression ProfilingGENETIC-ANALYSIS[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]lcsh:TP248.13-248.65GeneticsAnimalsMESH : Cluster AnalysisMESH: Central Nervous SystemAlleleMESH : DrosophilaAlleles030304 developmental biologyMESH : LarvaMicroarray analysis techniquesHOUSE-FLY LARVAGene Expression ProfilingMESH : Gene Expression ProfilingMESH: AllelesWild typeMESH : Nuclear ProteinsProsperobiology.organism_classificationMESH : Drosophila ProteinsMESH: Cluster AnalysisNERVOUS-SYSTEMGene expression profilinglcsh:GeneticsMESH: Oligonucleotide Array Sequence AnalysisHomeoboxMESH : AnimalsMESH : Gene Expression Regulation DevelopmentalMESH : AllelesMESH: Nuclear ProteinsMESH: Larva030217 neurology & neurosurgeryTranscription FactorsPATTERN-FORMATIONFINE-STRUCTURE
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages

2017

The quantity and activation state of adipose tissue macrophages (ATMs) impact the development of obesity-induced metabolic diseases. Appetite-controlling hormones play key roles in obesity; however, our understanding of their effects on ATMs is limited. Here, we have shown that human and mouse ATMs express NPFFR2, a receptor for the appetite-reducing neuropeptide FF (NPFF), and that NPFFR2 expression is upregulated by IL-4, an M2-polarizing cytokine. Plasma levels of NPFF decreased in obese patients and high-fat diet-fed mice and increased following caloric restriction. NPFF promoted M2 activation and increased the proliferation of murine and human ATMs. Both M2 activation and increased ATM…

Male0301 basic medicinemedicine.medical_specialty[SDV.BIO]Life Sciences [q-bio]/BiotechnologyUbiquitin-Protein LigasesAdipose tissue macrophagesMafB Transcription FactorAdipose tissueMice TransgenicReceptors Cell SurfaceSelf renewalMice03 medical and health sciencesClinical investigationInternal medicinemedicineAnimalsNeuropeptide FFTranscription factorAdaptor Proteins Signal TransducingCell ProliferationSTAT62. Zero hungerArginasebiologybusiness.industryChemistryMacrophagesProteinsSciences du Vivant [q-bio]/BiotechnologiesGeneral MedicineMacrophage ActivationInterleukin-10Ubiquitin ligaseCell biologyEndocrinology030104 developmental biologyAdipose TissueMAFBbiology.proteinInterleukin-4CorrigendumbusinessOligopeptidesMacrophage proliferationResearch ArticleJournal of Clinical Investigation
researchProduct

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, li…

2018

Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.

MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studies
researchProduct

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

2022

© 2022 Elsevier Inc.Background/objectives: Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset Still's disease (AOSD) mostly derive from small case series. Herein we report a registry-based study investigating TCZ efficacy and safety in a cohort of patients with AOSD evaluated by clinical and serum inflammatory markers as well as drug retention rate analysis. Methods: This is an international multicentre study analyzing data from patients with AOSD regularly enrolled in the AIDA registry. TCZ efficacy was evaluated between baseline and last follow-up assessment in terms of changes in the Pouchot score and laboratory findings. Drug-retention rate was estimated by the Kaplan-Mei…

RegistrieAdultMaleSettore MED/16 - REUMATOLOGIAInterleukin-6Innovative biotechnologiesTocilizumabAdult-onset Still's diseaseAntibodies Monoclonal HumanizedPersonalized medicineAdult-onset Still's disease; Innovative biotechnologies; Interleukin-6; Personalized medicine; TocilizumabSettore MED/38 - Pediatria Generale E SpecialisticaAnesthesiology and Pain MedicineRheumatologyInnovative biotechnologieStill's diseaseHumansFemaleRegistriesImmunotherapyTocilizumab.Still's Disease Adult-OnsetHuman
researchProduct

Distinguishing between two crus : as easy as picking the right side ? : Effect of expertise on conceptual and perceptual representations of Beaujolai…

2017

L’expertise a été étudiée en psychologie cognitive afin de comprendre les mécanismes psychologiques et les compétences intervenant dans différents domaines d’expertise. Dans le domaine du vin, les quelques études menées suggèrent que les experts organiseraient leurs connaissances autour de « prototypes » de couleur ou de cépage. L’objectif général de cette thèse visait à répondre aux questionnements théoriques concernant les représentations des vins d’experts et de novices, ainsi qu’aux questionnements de la filière concernant les perceptions des vins du Beaujolais. Pour cela, l’effet de l’expertise sur les représentations des vins a été évalué en comparant les performances de trois panels …

Représentation des connaissances[SDV.BIO]Life Sciences [q-bio]/BiotechnologyIngénierie des alimentsWineBiotechnologiesExpertisewine;categorization;expertise;knowledge representationCategorizationKnowledge representationAlimentation et NutritionVin[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood and NutritionFood engineering[SDV.AEN]Life Sciences [q-bio]/Food and NutritionCatégorisation
researchProduct

Avis en réponse à la saisine HCB - dossier C/NL/06/01_001. Paris, le 17 octobre 2018

2018

Le Haut Conseil des biotechnologies (HCB) a été saisi le 14 août 2018 par les autorités compétentes françaises (le ministère de l’Agriculture et de l’Alimentation) d’une demande d’avis relative au dossier C/NL/06/01_001 de demande de renouvellement d’autorisation de mise sur le marché de la lignée d’oeillets génétiquement modifiés 123.8.12 (identificateur unique FLO- 40689-6) à des fins d’importation et de commercialisation de fleurs coupées. Ce dossier a été déposé par la société Suntory Flowers Limited auprès des autorités compétentes néerlandaises sur le fondement de la directive 2001/18/CE. Conformément à cette directive, la Commission européenne a adressé le rapport d’évaluation des Pa…

[SDE] Environmental Sciences[SDV.BIO]Life Sciences [q-bio]/Biotechnology[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineering[SDV]Life Sciences [q-bio][SDV.GEN] Life Sciences [q-bio]/Genetics[SDV.GEN.GA] Life Sciences [q-bio]/Genetics/Animal geneticsorganisme génétiquement modifié[SHS]Humanities and Social Sciences[SDV.IDA]Life Sciences [q-bio]/Food engineering[SDV.BV]Life Sciences [q-bio]/Vegetal Biology[SDV.BV] Life Sciences [q-bio]/Vegetal Biology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringalimentationHaut conseil des biotechnologies[SDV.GEN]Life Sciences [q-bio]/GeneticsimportationOGM[SDV.IDA] Life Sciences [q-bio]/Food engineering[SDV.BIO] Life Sciences [q-bio]/Biotechnologyculture[SDV] Life Sciences [q-bio][SDV.GEN.GA]Life Sciences [q-bio]/Genetics/Animal geneticsplante[SDE]Environmental Sciencesexpertise[SHS] Humanities and Social Sciencesévaluation des risques
researchProduct

Commentaires sur le projet de document consensus de l’OCDE sur les considérations environnementales relatives à l’évaluation des risques associé. Par…

2018

Le Haut Conseil des biotechnologies (HCB) a été sollicité le 4 avril 2018 par la direction générale de l’alimentation du ministère de l’Agriculture et de l’Alimentation et par la direction générale de la prévention des risques du ministère de la Transition écologique et solidaire pour examiner et commenter le projet de document consensus de l’OCDE (version du 3 avril 2018) sur les considérations environnementales relatives à l’évaluation des risques associés à la dissémination de plantes génétiquement modifiées en vue de la réunion du groupe de travail de l’OCDE sur l’harmonisation de la surveillance réglementaire en biotechnologie les 21 et 22 juin 2018. Le Comité scientifique (CS)1 du HCB…

[SDE] Environmental Sciences[SDV.BIO]Life Sciences [q-bio]/Biotechnology[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineering[SDV]Life Sciences [q-bio][SDV.GEN] Life Sciences [q-bio]/Genetics[SDV.GEN.GA] Life Sciences [q-bio]/Genetics/Animal geneticsorganisme génétiquement modifié[SHS]Humanities and Social Sciences[SDV.IDA]Life Sciences [q-bio]/Food engineering[SDV.BV]Life Sciences [q-bio]/Vegetal Biology[SDV.BV] Life Sciences [q-bio]/Vegetal Biology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringalimentationHaut conseil des biotechnologies[SDV.GEN]Life Sciences [q-bio]/GeneticsimportationOGM[SDV.IDA] Life Sciences [q-bio]/Food engineering[SDV.BIO] Life Sciences [q-bio]/Biotechnologyculture[SDV] Life Sciences [q-bio][SDV.GEN.GA]Life Sciences [q-bio]/Genetics/Animal geneticsplante[SDE]Environmental Sciencesexpertise[SHS] Humanities and Social Sciencesévaluation des risques
researchProduct

Avis en réponse à la saisine HCB 150129 - dossier 2014-1211 concernant le dossier EFSA-GMO-NL-2014-121. Paris, le 22 avril 2015

2015

Le Haut Conseil des biotechnologies (HCB) a été saisi le 4 février 2015 par les autorités compétentes françaises (le ministère de l’Agriculture, de l’Agroalimentaire et de la Forêt) d’une demande d’avis relative à une évaluation du dossier EFSA-GMO-NL-2014-121 portant sur une demande d’autorisation de mise sur le marché du soja génétiquement modifié MON 87751 pour l’importation, la transformation, et l’alimentation humaine et animale. Ce dossier a été déposé par la société Monsanto auprès des autorités compétentes néerlandaises sur le fondement du règlement (CE) n° 1829/2003. Dans le cadre de ce règlement, l’évaluation des dossiers de demande de mise sur le marché est confiée à l’Autorité e…

[SDE] Environmental Sciences[SDV.BIO]Life Sciences [q-bio]/Biotechnology[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineering[SDV]Life Sciences [q-bio][SDV.GEN] Life Sciences [q-bio]/Genetics[SDV.GEN.GA] Life Sciences [q-bio]/Genetics/Animal geneticsorganisme génétiquement modifié[SHS]Humanities and Social Sciences[SDV.IDA]Life Sciences [q-bio]/Food engineering[SDV.BV]Life Sciences [q-bio]/Vegetal Biology[SDV.BV] Life Sciences [q-bio]/Vegetal Biology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringalimentationHaut conseil des biotechnologies[SDV.GEN]Life Sciences [q-bio]/GeneticsimportationOGM[SDV.IDA] Life Sciences [q-bio]/Food engineering[SDV.BIO] Life Sciences [q-bio]/Biotechnologyculture[SDV] Life Sciences [q-bio][SDV.GEN.GA]Life Sciences [q-bio]/Genetics/Animal geneticsplante[SDE]Environmental Sciencesexpertise[SHS] Humanities and Social Sciencesévaluation des risques
researchProduct